Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for suspected late-onset sepsis or necrotizing enterocolitis in extremely preterm infants
ACTRN12616000405415Phase 3Active, not recruiting
- Sponsor
- University of Sydney
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in late-onset neonatal sepsis (LONS) and necrotizing enterocolitis (NEC) comparing Pentoxifylline with Placebo (2 arms). Primary endpoint: Survival without disability at 24 months corrected age. Started Nov 2016; status: active, not recruiting.
02
Drugs
pentoxifylline
03
Conditions
late-onset neonatal sepsis (LONS)necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on ACTRN12616000405415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000405415.